NFlection Therapeutics
MA - BostonBiotechnology
Focus: NFlection Therapeutics is a Boston-based biotech company focused on developing therapies for Neurofibromatosis 1, a rare genetic disorder affecting the peripheral nervous system. The company operates in the pre-revenue stage with a focused pipeline targeting cutaneous and systemic manifestations of the disease.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Open Jobs
0
About NFlection Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow NFlection Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NFX-179 Gel
Neurofibromatosis 1Clinical Trials (1)
NCT04435665NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Phase 2Help build intelligence for NFlection Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.